GLP1R and Parkinson disease: When compared to other antidiabetic drug exposures, the results of additional analyses that censored follow-up time at the moment of stopping the index and comparator drugs demonstrated a clear protective connection between current exposure to GTZ, DPP4, and GLP-1 and PD [45].